Yaz, Yasmin, Ocella - Defective Drug Attorneys

Minneapolis - St. Paul, Twin Cities, Minnesota & Nationwide

If you have taken Yaz, Yasmin, or Ocella, and suffer from side effects, contact the Minneapolis defective drug attorneys of Goldenberg Law today for a consultation. 612-436-5026.

Yaz, Yasmin, and Ocella (the generic version) are birth control pills, manufactured by Bayer Healthcare Pharmaceuticals. In addition to being prescribed for birth control, Yaz, Yasmin, and Ocella were also marketed as treatments for emotional and physical symptoms of premenstrual dysphoric disorder (PMDD) and moderate acne.

Yasmin was approved by the FDA in 2001, and Yaz was approved in 2006. They contain a fourth generation progestin, called drospirenone (DSP), which is different than the hormones found in most other birth control medications. DSP has been found to increase potassium levels in women, thereby dehydrating the body. This dehydration has been found to increase the risk of many side-effects, such as cardiac arrhythmia, renal failure, pulmonary embolism (PE), heart attack, stroke, and even death. In addition to the increased potassium levels, drospirenone has also been shown to increase the risk of blood clots such as Deep vein thrombosis (DVT/blood clot in leg).

The manufacturers of Yaz, Yasmin, and Ocella marketed these products toward young, active, childbearing-aged women. In 2008, Bayer generated $616 million in sales of Yaz and an additional $382 in sales from Yasmin, making these products extremely lucrative for their manufacturer. However, the manufacturers failed to warn of the risks of dehydration and its associated complications. Women who are active and work out consistently can become even more dehydrated, thereby increasing their risk of the complications mentioned above.

The manufacturers of Yaz, Yasmin, and Ocella have been repeatedly disciplined by the FDA for their aggressive marketing of these products. In 2003, the FDA required Bayer Healthcare Pharmaceuticals to discontinue a television commercial that was deemed to mislead women as to the effectiveness and safety of these products. Not long after, the FDA also issued a warning letter to Bayer, because the company had overstated the drugs’ ability to improve the symptoms of PMDD and acne in another commercial. This time, Bayer was required to run a different set of commercials to correct the misleading information it previously distributed. However, even today, Bayer continues to aggressively market Yaz, Yasmin, and Ocella.

If you have taken Yaz, Yasmin, or Ocella, and you experienced any of the above conditions, please contact our Minneapolis defective drug attorneys by filling out our online contact form, or call our office for a complementary consultation.